Innovation Pharmaceuticals Inc (IPIX)

[biopa]

Based on the information released to date - Do I have my conclusions right?
- B significantly delays onset time for OM allowing patients time to complete radiation treatment
- B prevents OM in a portion of patients but numbers in PII may be too small to be stat sig.
- B may shorten OM duration but not enough information to draw a final conclusion
- B may lessen the severity of OM in patients, but it is too early to draw this conclusion
Based on the above, if results repeat, we have an approvable drug that every patient will demand and doctor will prescribe - if for no other reason than to complete radiation course. The other results are a super bonus. If any of them is stat sig in PHIII, B should take the market by storm. Looking forward to corrections. Don't claim to be MD or Statistician.